Scottish value-based assessments "can fix end-of-life treatment problem
This article was originally published in Scrip
Executive Summary
As it stands, Scotland's health technology appraisal system is not fit for purpose, according to James Jopling, Breakthrough Breast Cancer's Scotland Director. However, new value-based assessments for drugs announced by the Scottish government last week, with a focus on end-of-life drugs, should do something to help the situation.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.